Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aurinia Pharm Ord
(NQ:
AUPH
)
6.760
+0.110 (+1.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,701,506
Open
6.670
Bid (Size)
6.630 (2)
Ask (Size)
6.950 (2)
Prev. Close
6.650
Today's Range
6.620 - 6.940
52wk Range
4.710 - 10.24
Shares Outstanding
128,395,927
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
August 01, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
July 19, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Performance
YTD
-22.65%
-22.65%
1 Month
+20.71%
+20.71%
3 Month
+27.79%
+27.79%
6 Month
+12.67%
+12.67%
1 Year
-26.20%
-26.20%
More News
Read More
Aurinia to Participate in Upcoming Investor Healthcare Conferences
July 02, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces 2024 Annual General Meeting Results
June 14, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Earnings Scheduled For February 15, 2024
February 15, 2024
Via
Benzinga
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
June 05, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
June 04, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Provides Update on Proxy Statement
June 03, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
May 30, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
May 14, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
May 09, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
Via
InvestorPlace
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
May 02, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
May 01, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
April 30, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 16, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
April 15, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
April 09, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
February 29, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia to Participate in Upcoming Investor Healthcare Conferences
February 27, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
February 22, 2024
Via
Benzinga
Aurinia Pharmaceuticals Finds No Buyer After Strategic Business Review, Launches Stock Buyback
February 15, 2024
Via
Benzinga
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
February 15, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 15, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.